RxDoctor Payments Data

Maryanne Onitolo

Family · Cliffwood, NJNPI 1861645160

Payments from drug & device makers

$891in general payments, 2019–2025

Across 40 payments — averaging $22.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$400
  • Teva Pharmaceuticals USA, Inc.$205
  • Otsuka America Pharmaceutical, Inc.$126
  • Vanda Pharmaceuticals Inc.$81
  • EMD Serono, Inc.$32
  • SK Life Science, Inc.$27
  • plus $21 from 1 others

What the payments were for

  • Food & beverage$78087%
  • Education$11113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$891 in reported general payments places this provider in the 70th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$46,215
Medicare patients
80
Services billed
450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala57$239,446
Austedo XrDeutetrabenazine99$237,276
TivicayDolutegravir Sodium164$182,884
DescovyEmtricitabine/Tenofov Alafenam51$118,517
IsentressRaltegravir Potassium48$55,415
TriumeqAbacavir/Dolutegravir/Lamivudi13$49,435
EliquisApixaban112$33,078
EdurantRilpivirine Hcl32$22,920
VraylarCariprazine Hcl24$17,284
PrezcobixDarunavir/Cobicistat14$17,027
Darunavir42$16,909
RexultiBrexpiprazole15$10,903
JanuviaSitagliptin Phosphate35$9,851
Atovaquone17$8,491
Risperdal ConstaRisperidone Microspheres11$7,185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$205$237,27699 claims
Otsuka America Pharmaceutical, Inc.Rexulti$126$10,90315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,692 family providers in New Jersey.

Other family in Cliffwood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →